Certara Launches DIDB® Concomitant Meds Navigator, Extending Leadership in Drug Interaction Science Announcement Certara Launches DIDB® Concomitant Meds Navigator, Extending Leadership in Drug Interaction Science Meet DIDB Concomitant Meds Navigator—an evidence-based tool to identify contraindicated or monitored co-medications and manage…CertaraSeptember 22, 2025
Drug Interaction Database (DIDB ®) Fact Sheet Drug Interaction Database (DIDB ®) Optimize DDI knowledge throughout drug developmentCertaraSeptember 19, 2025
Certara Launches Libra™: AI-Powered Drug-Induced Liver Injury Prediction Tool Announcement Certara Launches Libra™: AI-Powered Drug-Induced Liver Injury Prediction Tool RADNOR, Pa. – September 17, 2025 – Certara, Inc. (Nasdaq: CERT), a global leader in…CertaraSeptember 17, 2025
Replacing Traditional TQT Studies with Model-Based Concentration-QTc (C-QTc) Analysis for Cardiovascular Safety in Drug Development Blog Replacing Traditional TQT Studies with Model-Based Concentration-QTc (C-QTc) Analysis for Cardiovascular Safety in Drug Development Learn how our experts use concentration-QTc (C-QTc) analysis to replace costly TQT studies, streamline QT…CertaraAugust 6, 2025
De-risking DDI Management during Clinical Trials: Introducing DIDB’s Concomitant Meds Navigator Webinar De-risking DDI Management during Clinical Trials: Introducing DIDB’s Concomitant Meds Navigator CertaraAugust 5, 2025
Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling Press Release Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling Certara announces that EMA has formally qualified the Simcyp® Simulator for use in regulatory submissions…CertaraAugust 4, 2025
What are the most common in vitro drug-drug interaction study gaps? Blog What are the most common in vitro drug-drug interaction study gaps? Certara drug interaction science experts share data and experimental design gaps commonly found in in…CertaraJune 9, 2025
Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions On-Demand Webinar Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions Director, Clinical Pharmacology, ORIC Pharmaceuticals SVP, Head of Simcyp PBPK Modeling Services, Certara Director, PBPK…CertaraApril 21, 2025
Measuring metabolites in index clinical DDI studies Blog Measuring metabolites in index clinical DDI studies February 7, 2025A key drug development safety consideration is whether the drug candidate will interact…CertaraFebruary 7, 2025